RSV Infection
75
11
16
38
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
13 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
5 terminated out of 75 trials
88.4%
+1.8% vs benchmark
4%
3 trials in Phase 3/4
34%
13 of 38 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 38 completed trials
Clinical Trials (75)
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
RSV Burden in Outpatient and Hospital Settings
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults